Cargando…
Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide
A 71-year-old woman with right chest and left lumbar pain was referred to our hospital. Computed tomography showed multiple recurrent tumors in the abdominal cavity and bilateral lungs. She had already received several chemotherapies for the recurrent tumor, and palliative care would be appropriate....
Autores principales: | Nakamura, Yasuhiko, Sanai, Hiromi, Miwa, Ichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372995/ https://www.ncbi.nlm.nih.gov/pubmed/30788108 http://dx.doi.org/10.1177/2050313X18819599 |
Ejemplares similares
-
A thick placenta: a predictor of adverse pregnancy outcomes
por: Miwa, Ichiro, et al.
Publicado: (2014) -
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002) -
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009) -
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997) -
Temozolomide and oral etoposide in children with recurrent malignant brain tumors
por: Ruggiero, Antonio, et al.
Publicado: (2020)